Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
News published by Savara Inc. concerning molgramostim nebulizer solution, a novel investigational inhaled biologic, administered via an optimized eFlow® Technology nebulizer.